Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops

Phytochemistry

Volumn 69, Issue 7, 2008, Pages 1534-1547

  Hall, Amy J ^a   Babish, John G ^b   Darland, Gary K ^a   Carroll, Brian J ^a   Konda, Veera Reedy ^a   Lerman, Robert H ^a   Bland, Jeffery S ^a   Tripp, Matthew L ^a  

^a Metagenics Inc   (United States)

^b MetaProteomics   (United States)

Author keywords

Anti inflammatory; Calprotectin; Cannabidaceae; Cyclooxygenase; Hops; Humulus lupulus L.; Knee osteoarthritis; NSAID; PGE2; Prostaglandin; Rho iso alpha acids

Indexed keywords

ALKANE; ANTIINFLAMMATORY AGENT; CALGRANULIN; CYCLOPENTANE DERIVATIVE; PLANT EXTRACT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; AGED; ANIMAL; ARTICLE; BIOAVAILABILITY; BODY WEIGHT; CELL LINE; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; FECES; FEMALE; HUMAN; HUMULUS; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; MALE; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; MOUSE; ORGAN SIZE; OSTEOARTHRITIS; PATHOLOGY; TREATMENT OUTCOME; URINE;

ADULT; AGED; ALKANES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CELL LINE; CHROMATOGRAPHY, LIQUID; CYCLOOXYGENASE INHIBITORS; CYCLOPENTANES; FECES; FEMALE; HUMANS; HUMULUS; KIDNEY; LEUKOCYTE L1 ANTIGEN COMPLEX; LIVER; MALE; MASS SPECTROMETRY; MICE; MIDDLE AGED; ORGAN SIZE; OSTEOARTHRITIS; PLANT EXTRACTS; PROSTAGLANDINS; TREATMENT OUTCOME;

CANNABACEAE; HUMULUS; HUMULUS LUPULUS;

EID: 42049102199     PISSN: 00319422     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phytochem.2008.02.001     Document Type: Article

References (46)

1. Anonymous, 2003. Humulus lupus. Monograph. Altern. Med. Rev. 8, 190-192.
2. Arroyo M., and Lanas A. NSAIDs-induced gastrointestinal damage. Rev. Miner. Gastroenterol. Dietol. 52 (2006) 249-259
3. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., and Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 15 (1988) 1833-1840
4. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K., Schnitzer, T.J., 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520-1528 (1522 page following 1528).
5. Brater D.C., Harris C., Redfern J.S., and Gertz B.J. Renal effects of COX-2-selective inhibitors. Am. J. Nephrol. 21 (2001) 1-15
6. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., and Baron J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352 (2005) 1092-1102
7. Capone M.L., Tacconelli S., Di Francesco L., Sacchetti A., Sciulli M.G., and Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostagland. Other Lipid Mediat. 82 (2007) 85-94
8. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., and Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 99 (2002) 13926-13931
9. Davidge S.T. Prostaglandin H synthase and vascular function. Circ. Res. 89 (2001) 650-660
10. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., and Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12 (1998) 1063-1073
11. Friden M., Vanaja K., and Nandi V.N. Drug-drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery. Drug Metabol. Drug Interact. 21 (2006) 163-185
12. Greenblatt D.J., von Moltke L.L., Perloff E.S., Luo Y., Harmatz J.S., and Zinny M.A. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin. Pharmacol. Ther. 79 (2006) 125-133
13. Grosser T., Fries S., and Fitzgerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116 (2006) 4-15
14. Guengerich F.P. Cytochromes P450, drugs, and diseases. Mol. Interv. 3 (2003) 194-204
15. Hall A.J., Tripp M., Howell T., Darland G., Bland J.S., and Babish J.G. Gastric mucosal cell model for estimating relative gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Prostagland. Leukot. Essent. Fatty Acid 75 (2006) 9-17
16. Hehner S.P., Hofmann T.G., Droge W., and Schmitz M.L. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J. Immunol. 163 (1999) 5617-5623
17. Hernandez-Diaz S., Varas-Lorenzo C., and Garcia Rodriguez L.A. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin. Pharmacol. Toxicol. 98 (2006) 266-274
18. Hla T., and Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA 89 (1992) 7384-7388
19. Holbrook A.M., Pereira J.A., Labiris R., McDonald H., Douketis J.D., Crowther M., and Wells P.S. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 165 (2005) 1095-1106
20. Holtzman M.J., Turk J., and Shornick L.P. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J. Biol. Chem. 267 (1992) 21438-21445
21. Institute of Laboratory Animal Research, C.o.L.S., National Research Council, 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
22. James M.J., and Cleland L.G. Cyclooxygenase-2 inhibitors: what went wrong?. Curr. Opin. Clin. Nutr. Metab. Care 9 (2006) 89-94
23. Konikoff M.R., and Denson L.A. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm. Bowel Dis. 12 (2006) 524-534
24. Kramer M. The toxicology of non-narcotic analgesics. Agent Action Suppl. 19 (1986) 225-236
25. Laine L., Connors L.G., Reicin A., Hawkey C.J., Burgos-Vargas R., Schnitzer T.J., Yu Q., and Bombardier C. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124 (2003) 288-292
26. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., Gomollon F., Feu F., Gonzalez-Perez A., Zapata E., Bastida G., Rodrigo L., Santolaria S., Guell M., de Argila C.M., Quintero E., Borda F., and Pique J.M. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006) 1731-1738
27. Lukaczer D., Darland G., Tripp M., Liska D., Lerman R.H., Schiltz B., and Bland J.S. A pilot trial evaluating Meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia. Phytother. Res. 19 (2005) 864-869
28. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., and FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA 96 (1999) 272-277
29. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
30. Meling T.R., Aabakken L., Roseth A., and Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand. J. Gastroenterol. 31 (1996) 339-344
31. Minich D.M., Bland J.S., Katke J., Darland G., Hall A., Lerman R.H., Lamb J., and Tripp M. Clinical safety and efficacy of NG440: a novel, synergistic combination of rho iso-alpha acids from hops, rosemary and oleanolic acid for inflammatory conditions. Can. J. Physiol. Pharmacol. 85 (2007) 872-883
32. Murakami M., Kambe T., Shimbara S., and Kudo I. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J. Biol. Chem. 274 (1999) 3103-3115
33. Nord L.I., Sorensen S.B., and Duus J.O. Characterization of reduced iso-alpha-acids derived from hops (Humulus lupulus) by NMR. Magn. Reson. Chem. 41 (2003) 660-670
34. Nozawa H., Nakao W., Zhao F., and Kondo K. Dietary supplement of isohumulones inhibits the formation of aberrant crypt foci with a concomitant decrease in prostaglandin E2 level in rat colon. Mol. Nutr. Food Res. 49 (2005) 772-778
35. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., Boyce S.W., and Verburg K.M. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352 (2005) 1081-1091
36. Ouellet M., Falgueyret J.P., and Percival M.D. Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. Biochem. J. 377 (2004) 675-684
37. Peura D.A. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am. J. Med. 117 Suppl. 5A (2004) 63S-71S
38. Poullis A., Foster R., Mendall M.A., and Fagerhol M.K. Emerging role of calprotectin in gastroenterology. J. Gastroenterol. Hepatol. 18 (2003) 756-762
39. Solomon S.D., Pfeffer M.A., McMurray J.J., Fowler R., Finn P., Levin B., Eagle C., Hawk E., Lechuga M., Zauber A.G., Bertagnolli M.M., Arber N., and Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114 (2006) 1028-1035
40. Tibble J.A., Sigthorsson G., Foster R., Scott D., Fagerhol M.K., Roseth A., and Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 45 (1999) 362-366
41. Topper J.N., Cai J., Falb D., and Gimbrone Jr. M.A. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA 93 (1996) 10417-10422
42. Tripp, M., Babish, J., Darland, G., Lerman, R., Lukaczer, D., Schiltz, B., Bland, J., 2004. Hop and modified hop extracts have potent in vitro anti-inflammatory properties. In: Proceedings of the First ISHS International Humulus Symposium, Corvallis, OR, USA.
43. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97-120
44. Vanegas H., and Schaible H.G. Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord. Prog. Neurobiol. 64 (2001) 327-363
45. Verzele M., and De Keukeleire D. Chemistry and Analysis of Hop and Beer Bitter Acids (1991), Elsevier, Amsterdam
46. Yamamoto K., Wang J., Yamamoto S., and Tobe H. Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid. FEBS Lett. 465 (2000) 103-106